Webcasts Event RSS
Upcoming Events Past Events
Morgan Stanley 2020 Virtual Global Healthcare Conference
September 17, 2020
View the live Webcast
Cantor 2020 Virtual Global Healthcare Conference
September 15, 2020
View the live Webcast
Wells Fargo 2020 Virtual Healthcare Conference
September 9, 2020
View the live Webcast

Investor Materials

Thumb Date Download
May 20, 2020 Corporate Presentation 721 KB
April 8, 2020 2019 Annual Report 1.46 MB
January 1, 2018 2018 Annual Report 939 KB
December 31, 2017 2017 Annual Report 3.18 MB
July 24, 2016 2016 Annual Report 4.75 MB
July 23, 2016 2015 Annual Report 5.24 MB
July 21, 2016 2014 Annual Report 2.13 MB

Recent News

Date Title Press Release RSS
Halozyme Announces Poster Presentation Of Data From Roche's Phase 1b Study Evaluating Atezolizumab For Subcutaneous Administration Utilizing Enhanze® In Non-Small Cell Lung Cancer 09/17/20
Halozyme Announces Janssen Submission For FDA Approval Of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) For The Treatment Of Patients With Light Chain (AL) Amyloidosis 09/10/20
Halozyme To Present At Upcoming Virtual Investor Conferences 09/09/20
Halozyme To Participate In 2020 Wells Fargo Virtual Healthcare Conference 09/02/20
See More

Investor Contacts

Al Kildani
Vice President, Investor Relations
& Corporate Communications
Phone: 858-704-8122
Email: akildani@halozyme.com
media@halozyme.com
ir@halozyme.com

Useful Links

Contact Info


Office:

Halozyme
11388 Sorrento Valley Road
San Diego, CA 92121
Phone: 858.794.8889
info@halozyme.com

Recent News

September 17, 2020 Halozyme Announces Poster Presentation Of Data From Roche's Phase 1b Study Evaluating Atezolizumab For Subcutaneous Administration Utilizing Enhanze® In Non-Small Cell Lung Cancer
September 10, 2020 Halozyme Announces Janssen Submission For FDA Approval Of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) For The Treatment Of Patients With Light Chain (AL) Amyloidosis
September 9, 2020 Halozyme To Present At Upcoming Virtual Investor Conferences
Copyright© 2015-2019. Halozyme, Inc. All rights reserved. All trademarks belong to their respective owners.
Powered By Q4 Inc. 5.42.0.2

Notice

You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.

Ok